New drug progress in diabetes! Takeda launches new type 2 diabetes compound Inisync (alogliptin/metformin) in Japan
New drug progress in diabetes! Takeda launches new type 2 diabetes compound Inisync (alogliptin/metformin) in Japan December 01, 2016 Source: Bio Valley November 30, 2016 / Bio Valley BIOON / -- Japanese pharmaceutical giant Takeda recently announced the launch of Inisync, a new diabetes drug in Japan, approved by Japanese regulatory authorities in October for type 2 diabetes (T2D) The treatment of the patient. The Inisync combination tablets consisted of a fixed dose of Nesina (alogliptin, 25 mg) and metformin (500 mg) administered orally once daily. This approval has made Inisync the only DPP-4 and metformin compound that is taken orally once a day in the Japanese market. The approval of Inisync is based on existing clinical data related to Nesina and Phase III clinical studies of Inisync in Japan. All of these clinical trials investigated the efficacy and safety of a combination of Nesina and metformin. Data from phase III clinical trials showed that Nesina+ metformin was administered simultaneously (once a day) to achieve a significantly greater reduction in glycated hemoglobin (HbA1c) compared to Nesina monotherapy and metformin monotherapy, reaching the main study end. In the study, the safety of simultaneous administration of Nesina and metformin was consistent with the safety of the two drugs alone. Nesina is an oral dipeptidyl peptidase-4 inhibitor (DPP-4i) that slows down incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptides. Inactivation of (GIP), thereby increasing the total amount of active incretins, allowing the pancreas to secrete insulin in a glucose-dependent manner, helping to manage blood sugar levels. Metformin is a biguanide that is often used as a first-line treatment for early treatment of type 2 diabetes, either alone or in combination with other drugs, including insulin. In patients with type 2 diabetes, the liver produces excess glucose, which pushes up blood sugar levels. Metformin can reduce the body's blood sugar level by reducing the amount of glucose produced by the liver, increasing muscle sensitivity to glucose, delaying glucose absorption in the intestine. Currently, both drugs have been widely used in the treatment of type 2 diabetes. The combination of DPP-4 inhibitor and metformin, with mechanism complementation and synergistic effect, will provide a more effective treatment option for the majority of type 2 diabetes populations. Can't stop with Lishida Chilli Sauce!As one of favourite sauce of people who love super spicy food,you could dip spring rolls,meatballs and dumplings,stir fry noodles,pork and beef or cook vegetables and tofu dishes,and seasoning various dishes.Lishida Chilli Sauce is made from selected chilli,water,salt and other safe ingredients.It is an indispensable sauce of many families and restaurants.This product is available for bulk wholesale,especially for supermarket,catering and home.Now Lishida Chilli Sauce includes red chilli sauce,sriracha chilli sauce,garlice chilli sauce and extra hot chilli sauce etc. Red Chilli Sauce, Garlic Chilli Sauce,Extra Hot Chilli Sauce,Sriracha Chilli Sauce KAIPING CITY LISHIDA FLAVOURING&FOOD CO.,LTD , https://www.lishidafood.com